108 related articles for article (PubMed ID: 31069776)
21. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
Grosso H; Mouradian MM
Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
[TBL] [Abstract][Full Text] [Related]
22. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
Song M; Hwang H; Im CY; Kim SY
J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
[TBL] [Abstract][Full Text] [Related]
23. Reaction profiling of a set of acrylamide-based human tissue transglutaminase inhibitors.
Jasim MH; Rathbone DL
J Mol Graph Model; 2018 Jan; 79():157-165. PubMed ID: 29179065
[TBL] [Abstract][Full Text] [Related]
24. Structure of natural variant transglutaminase 2 reveals molecular basis of gaining stability and higher activity.
Ha HJ; Kwon S; Jeong EM; Kim CM; Lee KB; Kim IG; Park HH
PLoS One; 2018; 13(10):e0204707. PubMed ID: 30321187
[TBL] [Abstract][Full Text] [Related]
25. How thioredoxin can reduce a buried disulphide bond.
Messens J; Van Molle I; Vanhaesebrouck P; Limbourg M; Van Belle K; Wahni K; Martins JC; Loris R; Wyns L
J Mol Biol; 2004 Jun; 339(3):527-37. PubMed ID: 15147840
[TBL] [Abstract][Full Text] [Related]
26. Transglutaminase 2 is expressed and active on the surface of human monocyte-derived dendritic cells and macrophages.
Hodrea J; Demény MA; Majai G; Sarang Z; Korponay-Szabó IR; Fésüs L
Immunol Lett; 2010 May; 130(1-2):74-81. PubMed ID: 20005901
[TBL] [Abstract][Full Text] [Related]
27. Transglutaminase 2: an enigmatic enzyme with diverse functions.
Fesus L; Piacentini M
Trends Biochem Sci; 2002 Oct; 27(10):534-9. PubMed ID: 12368090
[TBL] [Abstract][Full Text] [Related]
28. Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.
Klöck C; Herrera Z; Albertelli M; Khosla C
J Med Chem; 2014 Nov; 57(21):9042-64. PubMed ID: 25333388
[TBL] [Abstract][Full Text] [Related]
29. Neurite outgrowth inhibitory levels of organophosphates induce tissue transglutaminase activity in differentiating N2a cells: evidence for covalent adduct formation.
Almami IS; Aldubayan MA; Felemban SG; Alyamani N; Howden R; Robinson AJ; Pearson TDZ; Boocock D; Algarni AS; Garner AC; Griffin M; Bonner PLR; Hargreaves AJ
Arch Toxicol; 2020 Nov; 94(11):3861-3875. PubMed ID: 32749514
[TBL] [Abstract][Full Text] [Related]
30. Arterial vimentin is a transglutaminase substrate: a link between vasomotor activity and remodeling?
Gupta M; Greenberg CS; Eckman DM; Sane DC
J Vasc Res; 2007; 44(5):339-44. PubMed ID: 17476115
[TBL] [Abstract][Full Text] [Related]
31. Identification of DNAJA1 as a novel interacting partner and a substrate of human transglutaminase 2.
Ergülen E; Bécsi B; Csomós I; Fésüs L; Kanchan K
Biochem J; 2016 Nov; 473(21):3889-3901. PubMed ID: 27551108
[TBL] [Abstract][Full Text] [Related]
32. β
Vyas FS; Nelson CP; Freeman F; Boocock DJ; Hargreaves AJ; Dickenson JM
Eur J Pharmacol; 2017 Oct; 813():105-121. PubMed ID: 28754379
[TBL] [Abstract][Full Text] [Related]
33. Dissecting the interaction between transglutaminase 2 and fibronectin.
Cardoso I; Østerlund EC; Stamnaes J; Iversen R; Andersen JT; Jørgensen TJ; Sollid LM
Amino Acids; 2017 Mar; 49(3):489-500. PubMed ID: 27394141
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in understanding the roles of transglutaminase 2 in alcoholic steatohepatitis.
Tatsukawa H; Kojima S
Cell Biol Int; 2010 Feb; 34(3):325-34. PubMed ID: 20192918
[TBL] [Abstract][Full Text] [Related]
35. Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses.
Stephens P; Grenard P; Aeschlimann P; Langley M; Blain E; Errington R; Kipling D; Thomas D; Aeschlimann D
J Cell Sci; 2004 Jul; 117(Pt 15):3389-403. PubMed ID: 15199098
[TBL] [Abstract][Full Text] [Related]
36. Identification of thioredoxin disulfide targets using a quantitative proteomics approach based on isotope-coded affinity tags.
Hägglund P; Bunkenborg J; Maeda K; Svensson B
J Proteome Res; 2008 Dec; 7(12):5270-6. PubMed ID: 19367707
[TBL] [Abstract][Full Text] [Related]
37. Structural aspects of transglutaminase 2: functional, structural, and regulatory diversity.
Lee CS; Park HH
Apoptosis; 2017 Sep; 22(9):1057-1068. PubMed ID: 28677093
[TBL] [Abstract][Full Text] [Related]
38. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
[TBL] [Abstract][Full Text] [Related]
39. Regulation of ATPase activity of transglutaminase 2 by MT1-MMP: implications for mineralization of MC3T3-E1 osteoblast cultures.
Nakano Y; Forsprecher J; Kaartinen MT
J Cell Physiol; 2010 Apr; 223(1):260-9. PubMed ID: 20049897
[TBL] [Abstract][Full Text] [Related]
40. Isopeptidase activity of human transglutaminase 2: disconnection from transamidation and characterization by kinetic parameters.
Király R; Thangaraju K; Nagy Z; Collighan R; Nemes Z; Griffin M; Fésüs L
Amino Acids; 2016 Jan; 48(1):31-40. PubMed ID: 26250429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
